Organon & Co. OGN
NYSE · United States · Health Technology
$13.70-0.04 (-0.29%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Organon Canada, a global healthcare company, today announces the approval and availability of NDUVRA® (tapinarof cream), 1%, for the topical treatment of moderate to severe atopic dermatitis in adult and pediatric patients 2 years of age and older.
Why MIUDELLA’s FDA review matters for Organon stock Organon (OGN) just picked up fresh attention after the FDA accepted a supplemental application to extend use of MIUDELLA, a copper IUD that Organon licensed globally earlier this year. The device is already indicated for pregnancy prevention for up to 3 years, with an extended duration review underway and commercial availability targeted for late 2026. For investors watching Organon stock, this product sits squarely in the women’s health...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.